PBLS NASDAQ
Parabilis Medicines, Inc.
1W: -3.0%
1M: -24.5%
3M: +3.7%
YTD: +51.4%
$30.28
-0.16 (-0.53%)
Weekly Expected Move ±11.9%
$23
$27
$30
$34
$37
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$6.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.5B
52W Range20-42.49
Volume881,230
Avg Volume767,006
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMathai Mammen
Employees145
SectorHealthcare
IndustryBiotechnology
IPO Date2026-06-10
Websiteparabilismed.com
30 Acorn Park Dr
Cambridge, MA 02140
US
Cambridge, MA 02140
US
About Parabilis Medicines, Inc.
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Latest News
Parabilis Medicines (NASDAQ:PBLS) Shares Gap Up – Here’s What Happened
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
Market Movers | Winners: IVVD, PRTH, GRAL | Losers: EMAT, INDP, PBLS - Trefis
$PBLS stock is down 13% today. Here's what we see in our data. - quiverquant.com
Parabilis Medicines (NASDAQ:PBLS) Stock Price Down 6.3% - What's Next? - MarketBeat
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Tendler Craig | A-Award | 20,294 | $39.36 | 2026-08-22 |
| RA CAPITAL MANAGEMEN | P-Purchase | 47,250 | $29.77 | 2026-07-22 |
| RA CAPITAL MANAGEMEN | P-Purchase | 21,696 | $27.96 | 2026-07-21 |
| RA CAPITAL MANAGEMEN | P-Purchase | 6,504 | $29.17 | 2026-07-21 |
| RA CAPITAL MANAGEMEN | P-Purchase | 37,723 | $30.00 | 2026-07-21 |